WLF Ruling Offers No Viable Alternatives For Encouraging sNDAs - FDA Appeal
Executive Summary
The ruling overturning FDA's regulation of off-label reprint dissemination offers no viable alternatives for encouraging companies to file supplemental new drug applications, FDA's appeal of Washington Legal Foundation v. Henney argues.
You may also be interested in...
FDAMA Off-Label Provisions Were Premised On "Distrust" - Sen. Frist
One of the primary authors of the FDA Modernization Act off-label information dissemination compromise has declared his support for a federal court decision striking down the provisions.
FDAMA Off-Label Provisions Were Premised On "Distrust" - Sen. Frist
One of the primary authors of the FDA Modernization Act off-label information dissemination compromise has declared his support for a federal court decision striking down the provisions.
DTC Ad Regulation Could Be WLF's Next Constitutional Challenge
The Washington Legal Foundation is beginning to apply the same constitutional scrutiny it applied to off-label promotions to direct-to-consumer advertising.